Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone

Effects on insulin-like growth factor II

Ryszard Braczkowski, Andrew V Schally, Artur Plonowski, Jozsef L. Varga, Kate Groot, Magdalena Krupa, Patricia Armatis

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

BACKGROUND. Antagonists of growth hormone-releasing hormone (GH-RH) can inhibit the proliferation of various tumors either indirectly through the suppression of the pituitary growth hormone/hepatic insulin-like growth factor I (IGF-I) axis and the lowering of serum IGF-I concentration or directly by reducing the levels of IGF-I and IGF-II and their mRNA expression in tumors and blocking the effect of autocrine GH-RH. In this study, the authors investigated the effects of the GH-RH antagonist JV-1-38 on MNNG/HOS human osteosarcoma and SK-ES-1 human Ewing sarcoma cell lines. METHODS. Male nude mice bearing subcutaneous xenografts of MNNG/HOS or SK-ES-1 tumors were treated subcutaneously with JV-1-38 at a dose of 20 μg twice daily for 4 weeks. The concentrations of IGF-I and IGF-II in serum and in tumor tissue were measured by radioimmunoassay. Tumor and liver levels of mRNA for IGF-I and IGF-II were determined by reverse transcriptase-polymerase chain reaction analysis. The effects of JV-1-38, IGF-I, and IGF-II on cell proliferation in vitro were evaluated. RESULTS. GH-RH antagonist significantly (P < 0.05) inhibited the tumor volume and tumor weight of MNNG/HOS and SK-ES-1 tumors by > 50% after 4 weeks and increased tumor doubling time. JV-1-38 lowered the serum IGF-I level, decreased the expression of mRNA for IGF-I in the liver, and significantly (P < 0.05-0.01) reduced the concentration of IGF-II and mRNA levels for IGF-II in both sarcomas. The concentration of IGF-I was lowered only in SK-ES-1 tumors. In vitro, the proliferation of SK-ES-1 and MNNG/HOS cells was inhibited by JV-1-38 and by antisera to IGF-I and IGF-II. CONCLUSIONS. The inhibition of MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma by GH-RH antagonists was linked to a suppression of IGF-II production in tumors. However, in SK-ES-1 tumors, the effects on IGF-I also may be involved.

Original languageEnglish
Pages (from-to)1735-1745
Number of pages11
JournalCancer
Volume95
Issue number8
DOIs
StatePublished - Oct 15 2002
Externally publishedYes

Fingerprint

Methylnitronitrosoguanidine
Growth Hormone-Releasing Hormone
Ewing's Sarcoma
Insulin-Like Growth Factor II
Osteosarcoma
Insulin-Like Growth Factor I
Cell Line
Hormone Antagonists
Neoplasms
Messenger RNA
Liver
In Vitro Techniques
Serum
Reverse Transcriptase Polymerase Chain Reaction
Heterografts
Nude Mice
Sarcoma
Growth Hormone
Radioimmunoassay
Immune Sera

Keywords

  • Ewing sarcoma
  • Growth hormone-releasing hormone antagonists
  • Insulin-like growth factor I
  • Insulin-like growth factor II
  • Osteosarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone : Effects on insulin-like growth factor II. / Braczkowski, Ryszard; Schally, Andrew V; Plonowski, Artur; Varga, Jozsef L.; Groot, Kate; Krupa, Magdalena; Armatis, Patricia.

In: Cancer, Vol. 95, No. 8, 15.10.2002, p. 1735-1745.

Research output: Contribution to journalArticle

Braczkowski, Ryszard ; Schally, Andrew V ; Plonowski, Artur ; Varga, Jozsef L. ; Groot, Kate ; Krupa, Magdalena ; Armatis, Patricia. / Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone : Effects on insulin-like growth factor II. In: Cancer. 2002 ; Vol. 95, No. 8. pp. 1735-1745.
@article{c69275adf0584e809b3e26243dd98423,
title = "Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: Effects on insulin-like growth factor II",
abstract = "BACKGROUND. Antagonists of growth hormone-releasing hormone (GH-RH) can inhibit the proliferation of various tumors either indirectly through the suppression of the pituitary growth hormone/hepatic insulin-like growth factor I (IGF-I) axis and the lowering of serum IGF-I concentration or directly by reducing the levels of IGF-I and IGF-II and their mRNA expression in tumors and blocking the effect of autocrine GH-RH. In this study, the authors investigated the effects of the GH-RH antagonist JV-1-38 on MNNG/HOS human osteosarcoma and SK-ES-1 human Ewing sarcoma cell lines. METHODS. Male nude mice bearing subcutaneous xenografts of MNNG/HOS or SK-ES-1 tumors were treated subcutaneously with JV-1-38 at a dose of 20 μg twice daily for 4 weeks. The concentrations of IGF-I and IGF-II in serum and in tumor tissue were measured by radioimmunoassay. Tumor and liver levels of mRNA for IGF-I and IGF-II were determined by reverse transcriptase-polymerase chain reaction analysis. The effects of JV-1-38, IGF-I, and IGF-II on cell proliferation in vitro were evaluated. RESULTS. GH-RH antagonist significantly (P < 0.05) inhibited the tumor volume and tumor weight of MNNG/HOS and SK-ES-1 tumors by > 50{\%} after 4 weeks and increased tumor doubling time. JV-1-38 lowered the serum IGF-I level, decreased the expression of mRNA for IGF-I in the liver, and significantly (P < 0.05-0.01) reduced the concentration of IGF-II and mRNA levels for IGF-II in both sarcomas. The concentration of IGF-I was lowered only in SK-ES-1 tumors. In vitro, the proliferation of SK-ES-1 and MNNG/HOS cells was inhibited by JV-1-38 and by antisera to IGF-I and IGF-II. CONCLUSIONS. The inhibition of MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma by GH-RH antagonists was linked to a suppression of IGF-II production in tumors. However, in SK-ES-1 tumors, the effects on IGF-I also may be involved.",
keywords = "Ewing sarcoma, Growth hormone-releasing hormone antagonists, Insulin-like growth factor I, Insulin-like growth factor II, Osteosarcoma",
author = "Ryszard Braczkowski and Schally, {Andrew V} and Artur Plonowski and Varga, {Jozsef L.} and Kate Groot and Magdalena Krupa and Patricia Armatis",
year = "2002",
month = "10",
day = "15",
doi = "10.1002/cncr.10865",
language = "English",
volume = "95",
pages = "1735--1745",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone

T2 - Effects on insulin-like growth factor II

AU - Braczkowski, Ryszard

AU - Schally, Andrew V

AU - Plonowski, Artur

AU - Varga, Jozsef L.

AU - Groot, Kate

AU - Krupa, Magdalena

AU - Armatis, Patricia

PY - 2002/10/15

Y1 - 2002/10/15

N2 - BACKGROUND. Antagonists of growth hormone-releasing hormone (GH-RH) can inhibit the proliferation of various tumors either indirectly through the suppression of the pituitary growth hormone/hepatic insulin-like growth factor I (IGF-I) axis and the lowering of serum IGF-I concentration or directly by reducing the levels of IGF-I and IGF-II and their mRNA expression in tumors and blocking the effect of autocrine GH-RH. In this study, the authors investigated the effects of the GH-RH antagonist JV-1-38 on MNNG/HOS human osteosarcoma and SK-ES-1 human Ewing sarcoma cell lines. METHODS. Male nude mice bearing subcutaneous xenografts of MNNG/HOS or SK-ES-1 tumors were treated subcutaneously with JV-1-38 at a dose of 20 μg twice daily for 4 weeks. The concentrations of IGF-I and IGF-II in serum and in tumor tissue were measured by radioimmunoassay. Tumor and liver levels of mRNA for IGF-I and IGF-II were determined by reverse transcriptase-polymerase chain reaction analysis. The effects of JV-1-38, IGF-I, and IGF-II on cell proliferation in vitro were evaluated. RESULTS. GH-RH antagonist significantly (P < 0.05) inhibited the tumor volume and tumor weight of MNNG/HOS and SK-ES-1 tumors by > 50% after 4 weeks and increased tumor doubling time. JV-1-38 lowered the serum IGF-I level, decreased the expression of mRNA for IGF-I in the liver, and significantly (P < 0.05-0.01) reduced the concentration of IGF-II and mRNA levels for IGF-II in both sarcomas. The concentration of IGF-I was lowered only in SK-ES-1 tumors. In vitro, the proliferation of SK-ES-1 and MNNG/HOS cells was inhibited by JV-1-38 and by antisera to IGF-I and IGF-II. CONCLUSIONS. The inhibition of MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma by GH-RH antagonists was linked to a suppression of IGF-II production in tumors. However, in SK-ES-1 tumors, the effects on IGF-I also may be involved.

AB - BACKGROUND. Antagonists of growth hormone-releasing hormone (GH-RH) can inhibit the proliferation of various tumors either indirectly through the suppression of the pituitary growth hormone/hepatic insulin-like growth factor I (IGF-I) axis and the lowering of serum IGF-I concentration or directly by reducing the levels of IGF-I and IGF-II and their mRNA expression in tumors and blocking the effect of autocrine GH-RH. In this study, the authors investigated the effects of the GH-RH antagonist JV-1-38 on MNNG/HOS human osteosarcoma and SK-ES-1 human Ewing sarcoma cell lines. METHODS. Male nude mice bearing subcutaneous xenografts of MNNG/HOS or SK-ES-1 tumors were treated subcutaneously with JV-1-38 at a dose of 20 μg twice daily for 4 weeks. The concentrations of IGF-I and IGF-II in serum and in tumor tissue were measured by radioimmunoassay. Tumor and liver levels of mRNA for IGF-I and IGF-II were determined by reverse transcriptase-polymerase chain reaction analysis. The effects of JV-1-38, IGF-I, and IGF-II on cell proliferation in vitro were evaluated. RESULTS. GH-RH antagonist significantly (P < 0.05) inhibited the tumor volume and tumor weight of MNNG/HOS and SK-ES-1 tumors by > 50% after 4 weeks and increased tumor doubling time. JV-1-38 lowered the serum IGF-I level, decreased the expression of mRNA for IGF-I in the liver, and significantly (P < 0.05-0.01) reduced the concentration of IGF-II and mRNA levels for IGF-II in both sarcomas. The concentration of IGF-I was lowered only in SK-ES-1 tumors. In vitro, the proliferation of SK-ES-1 and MNNG/HOS cells was inhibited by JV-1-38 and by antisera to IGF-I and IGF-II. CONCLUSIONS. The inhibition of MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma by GH-RH antagonists was linked to a suppression of IGF-II production in tumors. However, in SK-ES-1 tumors, the effects on IGF-I also may be involved.

KW - Ewing sarcoma

KW - Growth hormone-releasing hormone antagonists

KW - Insulin-like growth factor I

KW - Insulin-like growth factor II

KW - Osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=0037108564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037108564&partnerID=8YFLogxK

U2 - 10.1002/cncr.10865

DO - 10.1002/cncr.10865

M3 - Article

VL - 95

SP - 1735

EP - 1745

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -